We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 137

Court grants motion to reopen trial and admit new evidence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 27 2011

The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued

Interlocutory injunction denied

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 29 2011

This was a motion for an interlocutory injunction

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 6 2013

The PMPRB has announced a Monitoring and Evaluation Plan for the Major Changes in the Guidelines. CIPO has announced a new PCT-Patent Prosecution

Appeal upholds dismissal of request to amend pleadings due to proximity to trial

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 4 2014

This case concerns an appeal of a motion to amend pleadings in the s. 8 case described above. The motion had originally been brought three months

The Court of Appeal sends s.8 case back to trial judge for redetermination

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 26 2012

The Federal Court of Appeal (FCA) has granted Apotex’ appeal and sent a case considering s. 8 of the Patented Medicines (Notice of Compliance) Regulations (the Regulations) back to the Trial Judge for redetermination

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 27 2010

The Government has published amendments to the Patented Medicines (Notice of Compliance) Regulations

Pfizer Canada Inc. v. Novopharm, The Minister of Health, Northwestern University and the Board of Regents for the University of Oklahoma

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 5 2010

In a proceeding pursuant to the Patented Medicines (Notice of Compliance) Regulations, Novopharm brought a motion seeking a Protective Order that allowed the designation of Novopharm's Notice of Allegation (NOA) as confidential

Court finds allegations in NOA to be unjustified, however dismisses application for prohibition on basis of mootness

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 18 2010

In this proceeding under the NOC Regulations, the Court found all of Apotex’ allegations to be unjustified

Court declares drug eligible for listing on the register of innovative drugs

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 13 2012

In this case, Celgene judicially reviewed a decision of the Minister of Health not to list their drug THALOMID thalidomide on the Register of Innovative Drugs (the Register

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 12 2012

The PMPRB has published Rules of Practice and Procedure in the Canada Gazette II